Nursing facilities are reminded that COVID-19 therapeutics are available for use in facilities and some are free of charge. The number of underlying conditions that make a person an eligible candidate for treatment are expanded.
These monoclonal antibody treatments are still indicated for symptomatic people who do not require hospitalization and are within 10-days of symptom onset.
Federal HHS notes the following for facilities:
- FDA has revoked the EUA for bamlanivimab used alone.
- The bamlanivimab/etesevimab combination retains its EUA. There is a pause in using it as a treatment right now because of the B.1.351 (Beta) and P.1 (Gamma) variants.
- REGEN-COV (casirivimab/imdevimab) is still available free of charge for facilities. They can order it directly from AmerisourceBergen.
- REGEN-COV can now be administered subcutaneously. Administration by IV infusion is still the preferred method, but subcutaneous administration is an option that is provided by the EUA. See Sections 2.2 Dosage and 2.4 Administration in the Fact Sheet for Health Care Providers (PDF) for details.
- Sotrovimab is a new monoclonal antibody treatment that has an EUA. But the federal government did not purchase a large quantity of this treatment. Facilities that order sotrovimab from AmerisourceBergen will be charged for it.
- Reimbursement for therapeutics from CMS has increased (PDF).